STRO - Sutro Biopharma - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

STRO is currently covered by 6 analysts with an average price target of $8.44. This is a potential upside of $7.62 (929.27%) from yesterday's end of day stock price of $0.82.

Sutro Biopharma's activity chart (see below) currently has 40 price targets and 55 ratings on display. The stock rating distribution of STRO is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 24.82% with an average time for these price targets to be met of 197.13 days.

Highest price target for STRO is $15, Lowest price target is $2, average price target is $8.

Most recent stock forecast was given by ANDREW FEIN from HC WAINWRIGHT on 17-Mar-2025. First documented stock forecast 22-Oct-2018.

Currently out of the existing stock ratings of STRO, 29 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$2

$0.9 (81.82%)

$12

2 months 20 days ago
(17-Mar-2025)

0/12 (0%)

$1.07 (115.05%)

Buy

$2

$0.9 (81.82%)

$8

2 months 23 days ago
(14-Mar-2025)

2/10 (20%)

$1.19 (146.91%)

708

Buy

2 months 23 days ago
(14-Mar-2025)

1/10 (10%)

$13.3 (359.46%)

24

Buy

$11

$9.9 (900.00%)

$12

7 months 26 days ago
(11-Oct-2024)

4/10 (40%)

$7.21 (190.24%)

402

Buy

$15

$13.9 (1263.64%)

$18

9 months 21 days ago
(16-Aug-2024)

2/7 (28.57%)

$10.79 (256.29%)

172

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is STRO (Sutro Biopharma) average time for price targets to be met?

On average it took 197.13 days on average for the stock forecasts to be realized with a an average price target met ratio 24.82

Which analyst has the current highest performing score on STRO (Sutro Biopharma) with a proven track record?

EDWARD TENTHOFF

Which analyst has the current lower performing score on STRO (Sutro Biopharma) with a proven track record?

JAY OLSON

Which analyst has the most public recommendations on STRO (Sutro Biopharma)?

Edward Tenthoff works at PIPER SANDLER and has 5 price targets and 4 ratings on STRO

Which analyst is the currently most bullish on STRO (Sutro Biopharma)?

Zhiqiang Shu with highest potential upside - $26.81

Which analyst is the currently most reserved on STRO (Sutro Biopharma)?

Reni Benjamin with lowest potential downside - -$0

Sutro Biopharma in the News

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

– Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization – – Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and PEGS, respectively – – Three INDs for wholly-owned programs anticipated in next 3 years, beginning with potential best-in-class Tissue Factor...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?